October 18, 2007 - SenoRx Inc. announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its SenoSonix System, an integration of its EnCor breast biopsy system with a state-of-the-art ultrasound imaging system, incorporating SenoRx's EnCor vacuum-assisted biopsy technologies with an ultrasound system developed and sold by Ultrasonix Medical Corporation of Canada.
SenoRx and Ultrasonix have enjoyed a close working relationship, jointly developing the technology that facilitates the integration of the two products. The product will be branded SenoSonix and marketed as SenoSonix with EnCor Inside.
For more information: www.senorx.com